A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
暂无分享,去创建一个
F. Uckun | C. Cogle | P. Patel | P. Shami | E. Cull | J. Watts | A. Mims | Anoush Shahidzadeh | Cynthia Lee | T. Lin
[1] F. Uckun,et al. Risk and Severity of Cytokine Release Syndrome in Patients with Relapsed/Refractory (R/R) AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436 , 2021, Blood.
[2] M. Heuser,et al. Treatment for Relapsed/Refractory Acute Myeloid Leukemia , 2021, HemaSphere.
[3] Byeong-Bae Park,et al. Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia , 2021, International journal of molecular sciences.
[4] Tamer Othman,et al. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia. , 2021, Future Oncology.
[5] J. Bewersdorf,et al. BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML? , 2021, Life.
[6] M. Konopleva,et al. Immunotherapy in Acute Myeloid Leukemia: Where We Stand , 2021, Frontiers in Oncology.
[7] N. Daver,et al. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments , 2021, Leukemia.
[8] S. Jamal,et al. Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome , 2021, Cell Reports Medicine.
[9] C. Craddock,et al. Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia , 2021, Frontiers in Oncology.
[10] M. Minden,et al. Venetoclax enhances T cell-mediated anti-leukemic activity by increasing ROS production. , 2021, Blood.
[11] F. Uckun,et al. Rejuveinix Shows a Favorable Clinical Safety Profile in Human Subjects and Exhibits Potent Preclinical Protective Activity in the Lipopolysaccharide-Galactosamine Mouse Model of Acute Respiratory Distress Syndrome and Multi‐Organ Failure , 2020, Frontiers in Pharmacology.
[12] F. Ravandi,et al. Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study , 2020, Blood.
[13] S. Rutella,et al. Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia , 2020 .
[14] T. Yau,et al. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. , 2020, Blood advances.
[15] P. Vyas,et al. New directions for emerging therapies in acute myeloid leukemia: the next chapter , 2020, Blood Cancer Journal.
[16] S. Rutella,et al. Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia. , 2020, Blood.
[17] A. Letai,et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.
[18] W. Blum,et al. Treating acute myeloid leukemia in the modern era: A primer , 2020, Cancer.
[19] P. Paschka,et al. Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML). , 2020 .
[20] M. Konopleva,et al. A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies. , 2020 .
[21] H. Einsele,et al. The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types , 2020, Cancer.
[22] M. Konopleva,et al. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. , 2020, Cancer discovery.
[23] F. Uckun,et al. A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia , 2019, Cancers.
[24] F. Uckun,et al. Recurrent or Refractory High-Grade Gliomas Treated by Convection-Enhanced Delivery of a TGFβ2-Targeting RNA Therapeutic: A Post-Hoc Analysis with Long-Term Follow-Up , 2019, Cancers.
[25] C. Dinardo,et al. How I treat acute myeloid leukemia in the era of new drugs. , 2019, Blood.
[26] M. Konopleva,et al. Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) , 2019, Blood.
[27] R. Larson,et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. , 2019, The New England journal of medicine.
[28] Kristen L. Jones,et al. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. , 2019, The Journal of clinical investigation.
[29] Catherine Lai,et al. Recent drug approvals for acute myeloid leukemia , 2019, Journal of Hematology & Oncology.
[30] D. Jablonski,et al. Abstract LB-199: APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity with limited cytokine release, is well tolerated in repeat dose toxicology studies in cynomolgus macaques , 2019, Immunology.
[31] W. Blum,et al. Progress in the problem of relapsed or refractory acute myeloid leukemia , 2019, Current opinion in hematology.
[32] F. Ferrara,et al. Current Therapeutic Results and Treatment Options for Older Patients with Relapsed Acute Myeloid Leukemia , 2019, Cancers.
[33] A. Letai,et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.
[34] J. Gross,et al. Abstract 1786: APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity, induces potent T-cell activation, proliferation and cytotoxicity with limited cytokine release , 2018, Immunology.
[35] W. Hiddemann,et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML , 2018, Leukemia.
[36] T. Chittenden,et al. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. , 2018, Blood advances.
[37] R. Schlenk,et al. Relapsed/refractory acute myeloid leukemia: any progress? , 2017, Current opinion in oncology.
[38] J. Blankenship,et al. Abstract 597: Bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecules for redirected T-cell cytotoxicity in hematological malignancies , 2017 .
[39] H. Kantarjian,et al. Emerging Molecular and Immune Therapies in Acute Myeloid Leukemia , 2017 .
[40] J. Cortes,et al. Treatment of Relapsed/Refractory Acute Myeloid Leukemia , 2017, Current Treatment Options in Oncology.
[41] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[42] Shery Jacob,et al. A simple practice guide for dose conversion between animals and human , 2016, Journal of basic and clinical pharmacy.
[43] M. Weiss,et al. Immunotherapy in acute myeloid leukemia , 2015, Cancer.
[44] C. Sentman,et al. Bispecific T‐cell engagers for cancer immunotherapy , 2015, Immunology and cell biology.
[45] S. Grupp,et al. Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.
[46] U. Testa,et al. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies , 2014, Biomarker Research.
[47] J. Dipersio,et al. Targeting CD123 In Leukemic Stem Cells Using Dual Affinity Re-Targeting Molecules (DARTs®) , 2013 .
[48] R. Solana,et al. Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. , 2013, Cytokine.
[49] M. Boyiadzis,et al. CD123 Immunohistochemical Expression in Acute Myeloid Leukemia is Associated With Underlying FLT3-ITD and NPM1 Mutations , 2012, Applied immunohistochemistry & molecular morphology : AIMM.
[50] S. Jang,et al. Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia , 2012, Annals of Hematology.
[51] J. Tamburini,et al. High levels of CD34+CD38low/−CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang (GOELAMS) study , 2011, Haematologica.
[52] F. Lo‐Coco,et al. Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations , 2011, British journal of haematology.
[53] Peter Lloyd,et al. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. , 2009, Current opinion in biotechnology.
[54] J. Dick,et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. , 2009, Cell stem cell.
[55] R. Foà,et al. Interleukin (IL)‐3/granulocyte macrophage‐colony stimulating factor/IL‐5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS‐related tyrosine kinase 3 receptor , 2009, British journal of haematology.
[56] H. Einsele,et al. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.
[57] A. Frankel,et al. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia , 2008, Leukemia & lymphoma.
[58] T. Lister,et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. , 2005, Blood.
[59] E. Coccia,et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. , 2002, Blood.
[60] Irving L. Weissman,et al. Prospective isolation of human clonogenic common myeloid progenitors , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[61] D. Howard,et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells , 2000, Leukemia.
[62] A. Ho,et al. Correlation Between IL‐3 Receptor Expression and Growth Potential of Human CD34+ Hematopoietic Cells from Different Tissues , 1999, Stem cells.
[63] G. Wagemaker,et al. Differential expression of receptors for hemopoietic growth factors on subsets of CD34+ hemopoietic cells. , 1996, Leukemia & lymphoma.
[64] K. Arai,et al. Expression and factor-dependent modulation of the interleukin-3 receptor subunits on human hematopoietic cells. , 1993, Blood.